<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25318" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Mucolytic Medications</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Rishab</given-names>
          </name>
          <aff>Sharda University, Sharda Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Wadhwa</surname>
            <given-names>Roopma</given-names>
          </name>
          <aff>South Carolina Department of Mental Health</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rishab Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Roopma Wadhwa declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25318.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Mucolytics are drugs used to manage mucus hypersecretion and its sequelae like recurrent infections in patients of COPD, cystic fibrosis, and bronchiectasis. They belong to a group of agents called mucoactive agents. This activity describes the different options and their respective mechanisms of action, indications, and contraindications pertinent for the healthcare team members as these are valuable agents in the management and treatment of productive cough and related muco-obstructive respiratory disorders.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanisms of action of the various classes of mucolytic agents.</p></list-item><list-item><p>Describe the adverse effects of mucolytic agents.</p></list-item><list-item><p>Review the appropriate monitoring for patients receiving mucolytic agents.</p></list-item><list-item><p>Outline the importance of improving interprofessional team strategies for enhancing communication and coordination to boost the outcomes in patients suffering from muco-obstructive disorders who are receiving mucolytic drugs.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25318&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25318">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25318.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Mucolytics are drugs belonging to the class of mucoactive agents. They exert their effect on the&#x000a0;mucus layer lining the respiratory tract with the motive of enhancing its clearance.&#x000a0;Mucus is the first line of defense for the various epithelia inside our body against harmful pathogens. Its job also entails the protection of the epithelium from the excoriating irritants found in the gastrointestinal tract. It houses an assemblage of proteins such as immunoglobulins, various glycoproteins, and even some antimicrobial enzymes like lysozyme. The cross-bridging of polymeric gel-forming mucins chiefly determines the biophysical properties of mucus. This layer is very protective against bacteria through bacterial growth inhibition and the prevention of biofilm formation. The mucus layer also works as a physical barrier against respiratory irritants and prevents fluid loss as well. Expectorated mucus is called sputum.&#x000a0;</p>
        <p>The amount of mucus in our body is regulated chiefly by&#x000a0;two mechanisms, which are the mucus-secreting cells and the&#x000a0;mucociliary escalator.&#x000a0;Goblet cells of the mucous membranes and the submucosal glands of the respiratory, GI, and reproductive systems are responsible for the secretion of mucus, and the mucociliary escalator is responsible for the clearance of mucus towards the pharynx, where it is eventually expectorated out by the cough reflex. However, there are some conditions where this regulation breaks down.</p>
        <p>In conditions like COPD<bold>&#x000a0;</bold>and<bold>&#x000a0;</bold>asthma,<bold>&#x000a0;</bold>chronic irritation of the airways leads to&#x000a0;mucus hypersecretion. Excessive mucus production overwhelms the mucociliary clearance mechanisms, thus leading to the accumulation of this excess mucus. This leads to the formation of mucus plugs, which further decrease the clearance. The airways respond by secreting an excess of inflammatory mediators in an attempt to clear the obstruction. Unfortunately, this only worsens the condition as mucus viscosity increases, leading to further decreased clearance as well as the initiation of inflammation and fibrosis. This condition is only worsened because this static mucus is invaded by bacteria like&#x000a0;<italic toggle="yes">Pseudomonas aeruginosa</italic>&#x000a0;and&#x000a0;<italic toggle="yes">Staphylococcus aureus.</italic>&#x000a0;Thus, a vicious cycle initiates, which invariably ends with an acute exacerbation of the condition. Classic mucolytics like&#x000a0;N-acetylcysteine are indicated in such conditions because they decrease mucus viscosity and increase its flowability, thereby improving its clearance.</p>
        <p>In conditions like cystic fibrosis, mucus secretion is impaired, and thus the airway secretions mostly include&#x000a0;filamentous actin polymers and inflammatory-cell derived DNA. These secretions are also thick and viscous and a frequent target of bacteria. Here, another class of mucolytics is helpful that targets the DNA polymers.&#x000a0;</p>
      </sec>
      <sec id="article-25318.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Mucolytics divide into two subgroups:</p>
        <p>1. Classic Mucolytics</p>
        <p>2. Peptide Mucolytics</p>
        <p>
<bold>Classic Mucolytics:</bold>
</p>
        <p>Disulfide bonds are building blocks of many&#x000a0;complex proteins, including mucus. N-acetyl L-cysteine (NAC), the prototype drug of this class,&#x000a0;reserves a reducing ability and works by the thiol-disulfide interchange mechanism.&#x000a0;The mucin polymers have cysteine residues throughout their structure. The disulfide bonds are anchored on these residues to yield crosslinking of the polymer.&#x000a0;The free thiol group in the structure of NAC hydrolyzes the disulfide bonds attached to cysteine residues. This reaction disturbs the 3-D framework of mucus by reducing the S-S bond to an S-H (sulfhydryl) bond,&#x000a0;rendering it incapable of anchoring the complex structure of the protein.<xref ref-type="bibr" rid="article-25318.r1">[1]</xref>&#x000a0;This subgroup includes</p>
        <p>
<bold>N - Acetylcysteine</bold>
</p>
        <p>Along with the above-mentioned mucolytic action, N-acetylcysteine also has anti-inflammatory and antioxidative properties. These agents help reduce the reactive oxygen species and inflammatory mediators that cause the insult in respiratory airways.</p>
        <p>
<bold>Carbocysteine</bold>
</p>
        <p>Carbocysteine also increases the volume of sputum, therefore producing an additional expectorative effect. It is very safe and effective in asthmatics as it does not irritate the respiratory tract.<xref ref-type="bibr" rid="article-25318.r2">[2]</xref>&#x000a0;It may be indicated for reducing AECOPD (acute exacerbation of chronic obstructive pulmonary disease)&#x000a0;due to its property of significantly reducing bacterial load in the airways of such patients.<xref ref-type="bibr" rid="article-25318.r3">[3]</xref>&#x000a0;Pulmonary infections have been implicated in up to 70% of all AECOPD.<bold>&#x000a0;</bold></p>
        <p>
<bold>Erdosteine and Fudosteine</bold>
</p>
        <p>These are newer drugs that are thiol derivatives and have additional anti-oxidant and anti-tussive actions. They have a sulfhydryl group in their active metabolite, called Met-1, which acts during the respiratory burst of the neutrophils.<xref ref-type="bibr" rid="article-25318.r4">[4]</xref>&#x000a0;Erdosteine has also shown a significant antibiotic-potentiating effect. Reports have also indicated that it is protective for alpha-1 antitrypsin.<xref ref-type="bibr" rid="article-25318.r5">[5]</xref></p>
        <p>
<italic toggle="yes">
<bold>Peptide Mucolytics</bold>
</italic>
</p>
        <p>In contrast to classic mucolytics, peptide mucolytics preserve the protective mucins. Peptide mucolytics target DNA polymers and F-actin links that tend to increase in purulent secretions. Therefore, peptide mucolytics, which are meant to reduce mucus viscosity by depolymerizing the DNA polymers or F-actin network that often present in purulent secretions, are very useful in conditions such as cystic fibrosis.</p>
        <p>
<bold>Dornase Alfa</bold>
</p>
        <p>Dornase alfa produces a mucolytic effect by depolymerizing DNA polymers. It produces a mild increase in FEV1(forced expiratory volume after 1 second) in patients with cystic fibrosis.<xref ref-type="bibr" rid="article-25318.r6">[6]</xref></p>
        <p>
<bold>Thymosin &#x003b2;4</bold>
</p>
        <p>The mucolytic effect of thymosin&#x000a0;&#x003b2;4 is produced through its effect on F-actin. F-actin is produced in a large quantity in purulent secretions and increases viscosity due to its filamentous nature. Thymosin may, therefore, be of&#x000a0;value in breaking down airway pus through the depolymerization of these filaments.<xref ref-type="bibr" rid="article-25318.r7">[7]</xref></p>
      </sec>
      <sec id="article-25318.s4" sec-type="Administration">
        <title>Administration</title>
        <p>N-acetylcysteine can be administered orally, intravenously, and topically in a nebulized form. Though the topical route offered the advantage of activating the mucociliary clearance mechanism along with inducing a cough reflex, the oral route offers much better tolerability.<xref ref-type="bibr" rid="article-25318.r8">[8]</xref> This is discussed further under adverse reactions. An oral dose of 200 to 600 mg daily is recommended for the management of muco-obstructive disorders.<xref ref-type="bibr" rid="article-25318.r9">[9]</xref>&#x000a0;The safety in pregnant females and children has been well established.<xref ref-type="bibr" rid="article-25318.r10">[10]</xref></p>
        <p>The recommended dose for dornase alfa is 2.5 mg administered in nebulized form 1&#x000a0;to 2 times a day for patients with cystic fibrosis.<xref ref-type="bibr" rid="article-25318.r6">[6]</xref>&#x000a0;Evidence suggests an improvement in FVC and FEV1 as soon as three days after initiating therapy. The standard therapies for cystic fibrosis, like antibiotics and chest physiotherapy, should be continued along with the drug. A similar dose and route of administration have been recommended for children of all age groups and adolescents. Early administration in infants and young children diagnosed with cystic fibrosis, even when no clinical signs or symptoms of the disease are present, has shown benefit.<xref ref-type="bibr" rid="article-25318.r11">[11]</xref>&#x000a0;Although there is limited data regarding the safety of Dornase alfa in pregnancy, no effect on fetal outcome was reported in animal models receiving dosages much higher than the maximum recommended human dose. &#x000a0;</p>
        <p>Carbocisteine is administered as an oral preparation, with dosages ranging from 750 mg twice a day to 4.5 g once a day. Evidence suggests that a higher concentration of active compounds was achieved via nocturnal administration of the drug.<xref ref-type="bibr" rid="article-25318.r2">[2]</xref></p>
        <p>Erdosteine is administered orally, and the doses can range from&#x000a0;600 to 900 mg. However, the dose should be titrated carefully in elderly patients with chronic liver disease as an increased plasma concentration, and elimination half-life have been reported in these cases.<xref ref-type="bibr" rid="article-25318.r5">[5]</xref></p>
      </sec>
      <sec id="article-25318.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <list list-type="bullet">
          <list-item>
            <p>The most frequently reported adverse effects of oral N-acetylcysteine are vomiting and diarrhea. After 16&#x000a0;to 18 days of N-acetylcysteine use, the incidence of vomiting and diarrhea increased by 50%&#x000a0;and 43.5%,&#x000a0;respectively.<xref ref-type="bibr" rid="article-25318.r9">[9]</xref><xref ref-type="bibr" rid="article-25318.r12">[12]</xref> Increased blood pressure, respiratory distress, chest pain, fever, rectal bleeding, headache, hypotension, lethargy, and skin allergy reportedly occur in less than 5% of cases. Aerosolized N-acetylcysteine is poorly tolerated due to its irritant effect and a very foul odor that can induce vomiting. A high incidence of anaphylactic reactions is observed in patients given intravenous N-acetylcysteine.<xref ref-type="bibr" rid="article-25318.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>The most commonly reported adverse reactions with Dornase alfa are laryngitis, voice alteration, and rash compared to placebo. Other less significant adverse were pharyngitis, chest pain, and conjunctivitis. These adverse effects were mostly transient and not reported to be severe enough to cause treatment withdrawal or require alterations in dosing. There have been no reports of an anaphylactic reaction to dornase alfa to date. Within all the studies, about 2&#x000a0;to 4% of patients treated with dornase alfa developed serum antibodies to the drug, the clinical significance of which is yet to be discerned.<xref ref-type="bibr" rid="article-25318.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Mild gastric discomfort, gastric ulceration, and fixed drug eruptions have been reported with carbocisteine.<xref ref-type="bibr" rid="article-25318.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Epigastralgia, headache, erythema, and nausea have been reported in patients receiving erdosteine, the latter two of which led to treatment discontinuation.<xref ref-type="bibr" rid="article-25318.r5">[5]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25318.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <list list-type="bullet">
          <list-item>
            <p>Due to its propensity to cause emesis, N-acetylcysteine is contraindicated in patients with peptic ulcers. It is also contraindicated in patients with esophageal varices and Mallory-Weiss tears due to similar reasons. It must be strictly avoided in patients who have had an anaphylactic reaction to the drug in the past.</p>
          </list-item>
          <list-item>
            <p>The only contraindication for dornase alfa is known hypersensitivity to the drug in the past or if the patient is hypersensitive to Chinese hamster ovary (CHO) cell products.<xref ref-type="bibr" rid="article-25318.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>Carbocysteine is contraindicated in patients with active gastric ulceration.<xref ref-type="bibr" rid="article-25318.r2">[2]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25318.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>After a 400 mg oral dose of N-acetylcysteine, the maximum plasma concentration was calculated to be 3.47 mg/L, taking 30 minutes to achieve it. The volume of distribution for N-acetylcysteine varies from 0.33 to 0.47 L/kg. 4 hours after an intravenous dose, 50% of the drug was found to be bound to plasma proteins. N-acetylcysteine undergoes extensive first-pass metabolism in the gut wall and liver when administered orally, leading to about 6&#x000a0;to 10% bioavailability. A majority of the elimination of this drug is non-renal, and the kidneys eliminated only 30%.<xref ref-type="bibr" rid="article-25318.r9">[9]</xref></p>
        <p>Animal studies have shown a minimal systemic absorption after aerosol inhalation of dornase alfa. Inhalation of even very high doses (10mg three times a day) did not significantly increase the serum DNase concentration.<xref ref-type="bibr" rid="article-25318.r15">[15]</xref>&#x000a0;Whatever little systemic absorption that does occur is believed to be protein-bound and is cleared from the body with no significant accumulation in the tissues.<xref ref-type="bibr" rid="article-25318.r16">[16]</xref><xref ref-type="bibr" rid="article-25318.r17">[17]</xref>&#x000a0;This implies that minimal to no monitoring is necessary for the patients receiving this drug. Following inhalation of a 2.5 mg dose of dornase alfa, a mean sputum concentration of 2&#x000a0;&#x003bc;g/mL was detected within the first 15 minutes, and 2 hours later, the concentration fell to 0.6&#x000a0;&#x003bc;g/mL. The disappearance half-life from the lungs in animal models was calculated to be about 11 hours. In primates, the bioavailability was less than 2%.<xref ref-type="bibr" rid="article-25318.r17">[17]</xref></p>
        <p>Carbocisteine shows&#x000a0;one-compartment open model kinetics after absorption and achieves its peak plasma concentration in 1 to 1.7 hours. The drug undergoes partial metabolism in the liver, and up to 60% of the drug is excreted by the kidneys unchanged.<xref ref-type="bibr" rid="article-25318.r2">[2]</xref></p>
        <p>Following oral administration, Erdosteine reaches its peak plasma concentration in 1.4 hours and has a similar elimination half-life. It contains two&#x000a0;sulfhydryl groups that are blocked. These are released only after its hepatic metabolism, which confers the valuable property of not affecting the mucus lining the stomach. No significant drug accumulation has been reported.<xref ref-type="bibr" rid="article-25318.r5">[5]</xref></p>
        <p>
<bold>Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Oral N-acetylcysteine must not be given with activated charcoal, as a 3 g preparation will adsorb 54.6% of the drug, and a 6 g preparation will adsorb 96.2% of the drug, markedly reducing its efficacy.<xref ref-type="bibr" rid="article-25318.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>N-Acetylcysteine provides local protection from the toxic metabolites of intravenous cyclophosphamide to the urethra, bladder, ureters, and kidneys when administered orally along with it.<xref ref-type="bibr" rid="article-25318.r18">[18]</xref></p>
          </list-item>
          <list-item>
            <p>Evidence suggests that N-Acetylcysteine can prevent doxorubicin-induced cardiomyopathy in animal models when co-administered.</p>
          </list-item>
          <list-item>
            <p>Dornase alfa has been shown to greatly potentiate the antibiotic effect of tobramycin and amikacin against multiple strains of <italic toggle="yes">Pseudomonas aeruginosa</italic> and <italic toggle="yes">Staphylococcus aureus.</italic><xref ref-type="bibr" rid="article-25318.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Administration of erdosteine with&#x000a0;amoxicillin in patients with an acute infective exacerbation of chronic bronchitis resulted in higher concentrations of the antibiotic in the sputum, leading to earlier and more pronounced amelioration of clinical symptoms compared with placebo.</p>
          </list-item>
          <list-item>
            <p>A higher concentration of amoxicillin in the sputum of patients suffering from an acute infective exacerbation of chronic bronchitis was reported when it was co-administered with erdosteine.<xref ref-type="bibr" rid="article-25318.r5">[5]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25318.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>N-acetylcysteine has a wide therapeutic index. Dosing errors, however, have led to instances of toxicity. These are more common with intravenous administration of the drug. There is a reported instance where ten times the recommended loading dose was administered to a 23-year old female.<xref ref-type="bibr" rid="article-25318.r13">[13]</xref>&#x000a0;This dose led to thrombocytopenia, hemolysis, acute renal failure, and ultimately death. Another study, however, showed that oral administration of N-acetylcysteine, as commonly used in patients with muco-obstructive disorders, is safer than intravenous route and dosing errors are much less likely.<xref ref-type="bibr" rid="article-25318.r19">[19]</xref>&#x000a0;Research has shown that oral doses as high as 30g/day for three days were very well tolerated, with minor adverse effects like vomiting and diarrhea.<xref ref-type="bibr" rid="article-25318.r12">[12]</xref></p>
        <p>Owing to its short half-life and poor systemic absorption, dornase alfa is a relatively well-tolerated drug. Toxicity to dornase alfa has not resulted in animal models exposed to doses as high as 180 times the maximum recommended human dose in single-dose inhalational studies.<xref ref-type="bibr" rid="article-25318.r14">[14]</xref></p>
        <p>Animal models have not shown any clinically significant toxicity to erdosteine even after administering very large doses of the drug.<xref ref-type="bibr" rid="article-25318.r5">[5]</xref></p>
      </sec>
      <sec id="article-25318.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>WHO projects the global prevalence of COPD to be about 250 million, with about 3 million deaths each year. Unfortunately, this figure is expected to rise in the coming years, equating to a substantial socio-economic impact. Therefore, while research for the definitive treatment of COPD continues, it is imperative to divert attention to therapies that could improve the lifestyle and reduce acute exacerbations, hospital stay, and mortality in such patients. This area is where mucolytics show immense potential.</p>
        <p>A well-coordinated interprofessional team of pulmonologists, physiotherapists, family clinicians (MDs, DOs, NPs, PAs), nurses, and pharmacists is required to work together to manage a case of COPD. First of all, the patient must be counseled regarding the importance of lifestyle modifications. The physician must instruct the patient thoroughly regarding the benefit of the prescribed drugs, the correct dose, the expected adverse reactions, and teaching them&#x000a0;the proper procedure for using a nebulizer. This approach will help maximize patient compliance. Patients must also receive education about the importance of regular follow-up visits. A crucial role is also played by clinical psychologists, support groups, and de-addiction centers, as this will help delay the disease progression in patients who smoke. This interprofessional approach to care with mucolytics in patients where appropriate can drive improved outcomes with fewer adverse events. [Level 5]</p>
        <p>In the last 30 years, great strides have occurred in the management of cystic fibrosis. Today, the median survival age of a patient is almost 40 years. This can, in part, be credited to the advancement in therapies like mucolytics. This effort can be furthered by utilizing a well-organized interprofessional team in its management. Although mucolytics prescribed by a physician are an important part of this, the role of nurses, chest physiotherapists, dieticians, and child psychiatrists&#x000a0;is also important.<xref ref-type="bibr" rid="article-25318.r20">[20]</xref>&#x000a0;</p>
        <p>Although the effectiveness of mucolytics has been challenged in recent times, the&#x000a0;evidence presented by large-scale studies conducted for N-acetylcysteine [Level 2], dornase alfa [Level 1], carbocisteine&#x000a0;[Level 1], and erdosteine [Level 2] cannot be ignored.<xref ref-type="bibr" rid="article-25318.r21">[21]</xref><xref ref-type="bibr" rid="article-25318.r22">[22]</xref><xref ref-type="bibr" rid="article-25318.r23">[23]</xref><xref ref-type="bibr" rid="article-25318.r24">[24]</xref></p>
      </sec>
      <sec id="article-25318.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25318&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25318">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25318/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25318">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25318.s11">
        <title>References</title>
        <ref id="article-25318.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sadowska</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Verbraecken</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Darquennes</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>De Backer</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>Role of N-acetylcysteine in the management of COPD.</article-title>
            <source>Int J Chron Obstruct Pulmon Dis</source>
            <year>2006</year>
            <volume>1</volume>
            <issue>4</issue>
            <fpage>425</fpage>
            <page-range>425-34</page-range>
            <pub-id pub-id-type="pmid">18044098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25318.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hooper</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Calvert</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease.</article-title>
            <source>Int J Chron Obstruct Pulmon Dis</source>
            <year>2008</year>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>659</fpage>
            <page-range>659-69</page-range>
            <pub-id pub-id-type="pmid">19281081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25318.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sun</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The effect and mechanism of action of carbocysteine on airway bacterial load in rats chronically exposed to cigarette smoke.</article-title>
            <source>Respirology</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>7</issue>
            <fpage>1064</fpage>
            <page-range>1064-71</page-range>
            <pub-id pub-id-type="pmid">20807377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25318.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dal Negro</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Erdosteine: antitussive and anti-inflammatory effects.</article-title>
            <source>Lung</source>
            <year>2008</year>
            <volume>186 Suppl 1</volume>
            <fpage>S70</fpage>
            <page-range>S70-3</page-range>
            <pub-id pub-id-type="pmid">18185958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25318.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dechant</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Noble</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Erdosteine.</article-title>
            <source>Drugs</source>
            <year>1996</year>
            <month>Dec</month>
            <volume>52</volume>
            <issue>6</issue>
            <fpage>875</fpage>
            <page-range>875-81; discussion 882</page-range>
            <pub-id pub-id-type="pmid">8957158</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25318.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bryson</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Sorkin</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Dornase alfa. A review of its pharmacological properties and therapeutic potential in cystic fibrosis.</article-title>
            <source>Drugs</source>
            <year>1994</year>
            <month>Dec</month>
            <volume>48</volume>
            <issue>6</issue>
            <fpage>894</fpage>
            <page-range>894-906</page-range>
            <pub-id pub-id-type="pmid">7533697</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25318.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rubin</surname>
                <given-names>BK</given-names>
              </name>
            </person-group>
            <article-title>Mucolytics, expectorants, and mucokinetic medications.</article-title>
            <source>Respir Care</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>52</volume>
            <issue>7</issue>
            <fpage>859</fpage>
            <page-range>859-65</page-range>
            <pub-id pub-id-type="pmid">17594730</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25318.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ziment</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Acetylcysteine: a drug with an interesting past and a fascinating future.</article-title>
            <source>Respiration</source>
            <year>1986</year>
            <volume>50 Suppl 1</volume>
            <fpage>26</fpage>
            <page-range>26-30</page-range>
            <pub-id pub-id-type="pmid">3809740</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25318.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holdiness</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics of N-acetylcysteine.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1991</year>
            <month>Feb</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>123</fpage>
            <page-range>123-34</page-range>
            <pub-id pub-id-type="pmid">2029805</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25318.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kortsalioudaki</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Cheeseman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bansal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mieli-Vergani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dhawan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Safety and efficacy of N-acetylcysteine in children with non-acetaminophen-induced acute liver failure.</article-title>
            <source>Liver Transpl</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-30</page-range>
            <pub-id pub-id-type="pmid">18161828</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25318.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nasr</surname>
                <given-names>SZ</given-names>
              </name>
              <name>
                <surname>Kuhns</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Hurwitz</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Sanders</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Strouse</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Use of computerized tomography and chest x-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: a preliminary study.</article-title>
            <source>Pediatr Pulmonol</source>
            <year>2001</year>
            <month>May</month>
            <volume>31</volume>
            <issue>5</issue>
            <fpage>377</fpage>
            <page-range>377-82</page-range>
            <pub-id pub-id-type="pmid">11340684</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25318.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Rumack</surname>
                <given-names>BH</given-names>
              </name>
            </person-group>
            <article-title>Clinical safety of high oral doses of acetylcysteine.</article-title>
            <source>Semin Oncol</source>
            <year>1983</year>
            <month>Mar</month>
            <volume>10</volume>
            <issue>1 Suppl 1</issue>
            <fpage>76</fpage>
            <page-range>76-85</page-range>
            <pub-id pub-id-type="pmid">6340205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25318.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahmoudi</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Astaraki</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mohtashami</surname>
                <given-names>AZ</given-names>
              </name>
              <name>
                <surname>Ahadi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>N-acetylcysteine overdose after acetaminophen poisoning.</article-title>
            <source>Int Med Case Rep J</source>
            <year>2015</year>
            <volume>8</volume>
            <fpage>65</fpage>
            <page-range>65-9</page-range>
            <pub-id pub-id-type="pmid">25767408</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25318.r14">
          <label>14</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Altaf</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Parmar</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Dornase Alfa</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">32310478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25318.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aitken</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Montgomery</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study.</article-title>
            <source>JAMA</source>
            <year>1992</year>
            <month>Apr</month>
            <day>08</day>
            <volume>267</volume>
            <issue>14</issue>
            <fpage>1947</fpage>
            <page-range>1947-51</page-range>
            <pub-id pub-id-type="pmid">1548827</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25318.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sinicropi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Championsmith</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ferraiolo</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mordenti</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Altered pharmacokinetics of recombinant human deoxyribonuclease in rats due to the presence of a binding protein.</article-title>
            <source>Drug Metab Dispos</source>
            <year>1993</year>
            <season>Jan-Feb</season>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>71</fpage>
            <page-range>71-5</page-range>
            <pub-id pub-id-type="pmid">8095230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25318.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Green</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Pharmaco-toxicological expert report Pulmozyme rhDNase Genentech, Inc.</article-title>
            <source>Hum Exp Toxicol</source>
            <year>1994</year>
            <month>May</month>
            <volume>13 Suppl 1</volume>
            <fpage>S1</fpage>
            <page-range>S1-42</page-range>
            <pub-id pub-id-type="pmid">8031609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25318.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Unverferth</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Leier</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Balcerzak</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Hamlin</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Usefulness of a free radical scavenger in preventing doxorubicin-induced heart failure in dogs.</article-title>
            <source>Am J Cardiol</source>
            <year>1985</year>
            <month>Jul</month>
            <day>01</day>
            <volume>56</volume>
            <issue>1</issue>
            <fpage>157</fpage>
            <page-range>157-61</page-range>
            <pub-id pub-id-type="pmid">4014022</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25318.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanter</surname>
                <given-names>MZ</given-names>
              </name>
            </person-group>
            <article-title>Comparison of oral and i.v. acetylcysteine in the treatment of acetaminophen poisoning.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2006</year>
            <month>Oct</month>
            <day>01</day>
            <volume>63</volume>
            <issue>19</issue>
            <fpage>1821</fpage>
            <page-range>1821-7</page-range>
            <pub-id pub-id-type="pmid">16990628</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25318.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ernst</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Stark</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Developmental and psychosocial issues in cystic fibrosis.</article-title>
            <source>Child Adolesc Psychiatr Clin N Am</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>263</fpage>
            <page-range>263-83, viii</page-range>
            <pub-id pub-id-type="pmid">20478499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25318.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cazzola</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Calzetta</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Page</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jardim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chuchalin</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Rogliani</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Matera</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis.</article-title>
            <source>Eur Respir Rev</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>24</volume>
            <issue>137</issue>
            <fpage>451</fpage>
            <page-range>451-61</page-range>
            <pub-id pub-id-type="pmid">26324807</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25318.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Montgomery</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Dornase alfa for cystic fibrosis.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2018</year>
            <month>Sep</month>
            <day>06</day>
            <volume>9</volume>
            <issue>9</issue>
            <fpage>CD001127</fpage>
            <pub-id pub-id-type="pmid">30187450</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25318.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zeng</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Effect of carbocisteine on patients with COPD: a systematic review and meta-analysis.</article-title>
            <source>Int J Chron Obstruct Pulmon Dis</source>
            <year>2017</year>
            <volume>12</volume>
            <fpage>2277</fpage>
            <page-range>2277-2283</page-range>
            <pub-id pub-id-type="pmid">28814855</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25318.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dal Negro</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Wedzicha</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Iversen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Page</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cicero</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Pozzi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Calverley</surname>
                <given-names>PMA</given-names>
              </name>
              <collab>RESTORE group</collab>
              <collab>RESTORE study</collab>
            </person-group>
            <article-title>Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study.</article-title>
            <source>Eur Respir J</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>50</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">29025888</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
